PSI Sci
New here? Follow the money and the votes · Not sure of your district? Find your U.S. House member · Find your state legislators

S. 1551: Protecting Free Trade in Pharmaceuticals Act of 2005

Before you vote › Federal bills

S. 1551: Protecting Free Trade in Pharmaceuticals Act of 2005

109th Congress · introduced 2005-07-28 · Foreign Trade and International Finance · Latest: Read twice and referred to the Committee on Finance.

federal

Follow this bill, step by step

  1. Where it came from: introduced 2005-07-28 · official record
  2. Who proposed it: Sen. Vitter, David [R-LA] · what a sponsor is
  3. What happened next: no floor votes in our records yet. Why?
  4. Where it stands now: Read twice and referred to the Committee on Finance. Not final yet: this can still change. We check for updates every day.
  5. If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.

What does this mean?

Official title

Protecting Free Trade in Pharmaceuticals Act of 2005

Plain summary

Protecting Free Trade in Pharmaceuticals Act of 2005 - Amends the Bipartisan Trade Promotion Authority Act of 2002 to include among the overall trade negotiating objectives of the United States avoiding negotiating trade agreements that could restrict, or be interpreted to restrict, the access of consumers in the United States to pharmaceutical imports from countries with a pharmaceutical infrastructure that is equivalent, or superior, to that of the United States: (1) by or through the use and development of the doctrine of international patent exhaustion, as interpreted or applied by U.S. courts on the enactment of this Act; or (2) by making it a violation for the United States to enact legislation permitting pharmaceutical imports without the consent of patent owners when the products involved have been sold outside the United States. Prohibits the U.S. Trade Representative (USTR) from: (1) entering into a bilateral or multilateral trade agreement that, with respect to the importation of pharmaceutical products without the consent of the patent owners, includes provisions identical or similar to the provisions of the United States-Singapore Free Trade Agreement, the United States-Australia Free Trade Agreement, or the United States-Morocco Free Trade Agreement; or (2) negotiating an agreement or understanding with respect to any of such provisions. Requires the USTR, with respect to the advisory committee on matters relating to intellectual property, to ensure that, for each meeting that relates or potentially relates to the importation of pharmaceutical products into the United States, at least 10% of the committee members represent the interests of consumers of such products.

Congressional Research Service summary (Introduced in Senate), quoted unchanged (nonpartisan). Read the source.

What a vote does

A “Yea” vote

If it passes both chambers and is signed, it becomes law.

A “Nay” vote

If it is not passed, current law stays as it is.

PSI Sci description of the legislative step (not an opinion).

What does this mean? (plain words)

Official text

Protecting Free Trade in Pharmaceuticals Act of 2005

Source: Congressional Research Service summary (Introduced in Senate)

AI explanation – may be wrong, check the official text

No AI explanation yet. It takes up to a minute to write and is then saved for everyone.

Limited to a few requests an hour per person.

The strongest published arguments

Arguments for (supporters)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Arguments against (opponents)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Sen. Vitter, David [R-LA] · 2 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Sources

Record fed-us-cong109-s1551 · catalog fed-us-congress-bills-cong109 · updated 2026-11-15 by psicol fed-bills-cong109